GlassScriptPhysician profile
Judy P Phillips
NPI 1679659742
$2,150.77
in general payments reported to CMS, 2019-2025
25 companies · $76.00 in 2025
The $76.00 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $249 · 2023: $1,368 · 2024: $290 · 2025: $76.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $960 · Food and Beverage: $675 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $960.00 |
| Food and Beverage | $674.50 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $960.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $199.93 | 2021-2024 | |
| Astellas Pharma US INC | $160.90 | 2023-2024 | Padcev |
| Janssen Biotech, INC. | $155.58 | 2021-2024 | Talvey, Imbruvica, Darzalex |
| Abbvie INC. | $97.51 | 2021-2025 | |
| Eisai INC. | $66.12 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $53.74 | 2024 | Keytruda, Reblozyl |
| Seagen INC. | $51.31 | 2021-2023 | Adcetris |
| Astrazeneca Pharmaceuticals LP | $45.89 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.59 | 2024 | Fruzaqla |
| Morphosys, US INC. | $31.37 | 2022 | |
| Incyte Corporation | $31.03 | 2022-2024 | Monjuvi |
| Amgen INC. | $30.19 | 2021-2023 | Blincyto, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $27.85 | 2021-2024 | Opdivo |
| Gilead Sciences, INC. | $22.86 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $21.65 | 2024 | |
| Agios Pharmaceuticals, INC. | $20.72 | 2024 | Pyrukynd |
| Deciphera Pharmaceuticals INC. | $20.45 | 2023 | Qinlock |
| Pharmaessentia USA Corporation | $19.68 | 2023 | Besremi |
| Genentech USA, INC. | $19.13 | 2022 | |
| Aveo Pharmaceuticals, INC. | $18.18 | 2023 | Fotivda |
| Pharmacosmos Therapeutics INC. | $17.49 | 2024 | Cosela |
| Exelixis INC. | $17.29 | 2021 | |
| Myriad Genetic Laboratories, INC. | $15.36 | 2024 | Myrisk |
| Epizyme, INC. | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judy Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.